Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Everolimus Versus Cabozantinib in mRCC Progressed on PD-1/PD-L1
NCT05012371Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2022
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib and everolimus in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Progression-Free Survival up to 2 years. Started Feb 2022; status: active, not recruiting.
02
Drugs
lenvatinibeverolimus
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05012371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05012371.